EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 19 / No 5 (Mai 2003) Med Sci (Paris), 19 5 (2003) 593-599 References
Free Access
Issue
Med Sci (Paris)
Volume 19, Number 5, Mai 2003
Page(s) 593 - 599
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2003195593
Published online 15 May 2003
  1. The Huntington’s disease collaborative research group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 1993; 72: 971–83. [Google Scholar]
  2. Mangiarini L, Sathasivam K, Seller M, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996; 87: 493–506. [Google Scholar]
  3. Davies SW, Turmaine M, Cozens BA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997; 90: 537–48. [Google Scholar]
  4. Reddy PH, Williams M, Charles V, et al. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated fulllength HD cDNA. Nat Genet 1998; 20: 198–202. [Google Scholar]
  5. Hodgson JG, Agopyan N, Gutekunst CA, et al. A YAC mouse model for Huntington’s disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 1999; 23: 181–92. [Google Scholar]
  6. Lin CH, Tallaksen-Greene S, Chien WM, et al. Neurological abnormalities in a knock-in mouse model of Huntington’s disease. Hum Mol Genet 2001; 10: 137–44. [Google Scholar]
  7. Menalled LB, Sison JD, Wu Y, et al. Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington’s disease knock-in mice. J Neurosci 2002; 22: 8266–76. [Google Scholar]
  8. Wheeler VC, Gutekunst CA, Vrbanac V, et al. Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice. Hum Mol Genet 2002; 11: 633–40. [Google Scholar]
  9. Steffan JS, Bodai L, Pallos J, et al. Histone deacetylase inhibitors arrest polyglutaminedependent neurodegeneration in Drosophila. Nature 2001; 413: 739–43. [Google Scholar]
  10. Kazantsev A, Walker HA, Slepko N, et al. A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila. Nat Genet 2002; 30: 367–76. [Google Scholar]
  11. Jackson GR, Salecker I, Dong X, et al. Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. Neuron 1998; 21: 633–42. [Google Scholar]
  12. Kazemi-Esfarjani P, Benzer S. Genetic suppression of polyglutamine toxicity in Drosophila. Science 2000; 287: 1837–40. [Google Scholar]
  13. Marsh JL, Walker H, Theisen H, et al. Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila. Hum Mol Genet 2000; 9:13–25. [Google Scholar]
  14. Perutz MF, Johnson T, Suzuki M, Finch JT. Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci USA 1994; 91: 5355–8. [Google Scholar]
  15. Green H. Human genetic diseases due to codon reiteration: relationship to an evolutionary mechanism. Cell 1993; 74: 955–6. [Google Scholar]
  16. Cooper AJ, Jeitner TM, Gentile V, Blass JP. Cross linking of polyglutamine domains catalyzed by tissue transglutaminase is greatly favored with pathological-length repeats: does transglutaminase activity play a role in (CAG)(n)/Q(n)-expansion diseases ? Neurochem Int 2002; 40: 53–67. [Google Scholar]
  17. Mastroberardino PG, Iannicola C, Nardacci R, et al. Tissue transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington’s disease. Cell Death Differ 2002; 9: 873–80. [Google Scholar]
  18. McCampbell A, Taylor JP, Taye AA, et al. CREBbinding protein sequestration by expanded polyglutamine. Hum Mol Genet 2000; 9: 2197–202. [Google Scholar]
  19. Jana NR, Tanaka M, Wang G, Nukina N. Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity. Hum Mol Genet 2000; 9: 2009–18. [Google Scholar]
  20. Levine MS, Klapstein GJ, Koppel A, et al. Enhanced sensitivity to N-methyl-Daspartate receptor activation in transgenic and knock-in mouse models of Huntington’s disease. J Neurosci Res 1999; 58: 515–32. [Google Scholar]
  21. Cha JH. Transcriptional dysregulation in Huntington’s disease. Trends Neurosci 2000; 23: 387–92. [Google Scholar]
  22. Liévens J, Woodman B, Mahal A, Bates G. Abnormal phosphorylation of synapsin I predicts a neuronal transmission impairment in the R6/2 Huntington’s disease transgenic mice. Mol Cell Neurosci 2002; 20: 638–48. [Google Scholar]
  23. Liévens JC, Woodman B, Mahal A, et al. Impaired glutamate uptake in the R6 Huntington’s disease transgenic mice. Neurobiol Dis 2001; 8: 807–21. [Google Scholar]
  24. Ferrante RJ, Andreassen OA, Dedeoglu A, et al. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington’s disease. J Neurosci 2002; 22: 1592–9. [Google Scholar]
  25. Rosas HD, Koroshetz WJ, Jenkins BG, et al. Riluzole therapy in Huntington’s disease. Mov Disord 1999; 14: 326–30. [Google Scholar]
  26. Tabrizi SJ, Cleeter MW, Xuereb J, et al. Biochemical abnormalities and excitotoxicity in Huntington’s disease brain. Ann Neurol 1999; 45: 25–32. [Google Scholar]
  27. Laforet GA, Sapp E, Chase K, et al. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington’s disease. J Neurosci 2001; 21: 9112–23. [Google Scholar]
  28. Schilling G, Becher MW, Sharp AH, et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 1999; 8: 397–407. [Google Scholar]
  29. Shelbourne PF, Killeen N, Hevner RF, et al. A Huntington’s disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. Hum Mol Genet 1999; 8: 763–74. [Google Scholar]
  30. Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington’s disease. Cell 2000; 101: 57–66. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.